Congress is going after drug prices. Pharma CEOs aren't panicking, yet

In the Senate, lawmakers have proposed legislation that would penalize drugmakers hiking the prices of their products above the rate of inflation.

Down Pennsylvania Avenue at the White House, the Trump administration has come out with plans to permit limited importing of drugs from abroad.

Both ideas are anathema to the drug industry, which has forcefully argued against government-imposed restrictions on pricing and the foreign sourcing of drugs. Yet pharma CEOs, presenting their companies' outlook amid release of second quarter earnings this week and last, don't appear to be panicking.